Who Owns Amgen?
Amgen is the master brand of Amgen Inc. (Nasdaq: AMGN), the biotechnology company headquartered in Thousand Oaks, California. The brand covers the company's full portfolio of biologic medicines including Enbrel, Prolia, Otezla, and Neulasta across inflammation, oncology, and rare disease. Parent FY2025 revenue was $36.8 billion.
Who Owns Amgen?
- Parent Company: Amgen Inc.
- Ownership Type: Brand division
- Company Type: Publicly Traded
- Stock Ticker: NASDAQ: AMGN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Amgen | Amgen Inc. | Brand division |
Where to Buy
Disclosure: We may earn commission from purchases
Amgen on AmazonHistory of Amgen
- Founded: 1980
- Founders: George Rathmann
George Rathmann founded Applied Molecular Genetics in 1980 in Thousand Oaks, California, one of the pioneering biotechnology companies applying recombinant DNA technology to medicine. The Amgen name derives from the original.
The brand became synonymous with biologics through the success of Epogen in 1989 and Neupogen in 1991, the first biotechnology blockbusters that established the field. These products defined the brand's identity as a biologics company rather than a conventional pharmaceutical maker.
The 2002 Immunex acquisition added Enbrel, making Amgen the owner of one of the highest-selling drugs in history and cementing its inflammation franchise. The 2023 Horizon Therapeutics acquisition for $27.8 billion added rare disease products under the Amgen identity.
FY2025 was a record commercial year: revenue grew 10% to $36.8 billion with fourteen products exceeding $1 billion in sales, demonstrating the breadth the Amgen brand has built across its portfolio.
About Amgen Inc.
What does Amgen own?
Amgen owns the Amgen brand and product brands including Enbrel, Prolia, Otezla, Neulasta, Repatha, Tezspire, and others. The Horizon acquisition added Tepezza, Krystexxa, and Uplizna.
Is Amgen publicly traded?
Yes. Amgen trades on Nasdaq under ticker AMGN and is a component of the S&P 500 and Dow Jones Industrial Average.
Who founded Amgen?
George Rathmann founded Applied Molecular Genetics in 1980 in Thousand Oaks, California. The name Amgen derives from the original.
Where is Amgen headquartered?
Amgen is headquartered in Thousand Oaks, California, USA.
Who owns Amgen?
Amgen is owned by public shareholders with no controlling investor. Robert Bradway serves as Chairman and CEO.
What is Amgen's revenue?
Amgen reported FY2025 total revenues of $36.8 billion, up 10%, with GAAP net income of $7.7 billion and non-GAAP EPS of $21.84.
What does Amgen make?
Amgen makes biologic medicines including Enbrel for rheumatoid arthritis, Prolia for osteoporosis, Otezla for psoriasis, and oncology and rare disease treatments.
- Founded: 1980
- Headquarters: Thousand Oaks, California, USA
- Company Type: Publicly Traded
- Stock: NASDAQ: AMGN
- Revenue: $36.8 billion (FY2025)
- Employees: Approximately 28,000
Where Is Amgen Made / Based?
- Headquarters: Thousand Oaks, California, USA
- Manufacturing / Operations: United States, Puerto Rico, Ireland, Singapore
Amgen Categories & Tags
Amgen Recalls & Controversies
As a pharmaceutical company, Amgen's controversies are drug pricing, patent litigation, and regulatory matters.
IRA drug pricing: The Medicare price-setting selection affecting Otezla and other products is the leading edge of IRA-driven pricing pressure across the industry, with Amgen a prominent affected company.
Drug pricing scrutiny: High US list prices for biologics including Enbrel draw the same political scrutiny affecting all major pharma companies on drug affordability.
Patent litigation: Amgen engages in significant patent battles both defending its biologics against biosimilars and challenging competitors' patents for its own biosimilar business, standard industry litigation.
Brands Owned by Amgen Inc.
Healthcare PharmaceuticalsEnbrel
Owned by Amgen Inc.
Biologic medication for rheumatoid arthritis and autoimmune conditions, owned by Amgen Inc., one of the highest-selling drugs in pharmaceutical history.
pharmaceuticalsbiologicsrheumatoid-arthritis
Healthcare PharmaceuticalsNeulasta
Owned by Amgen Inc.
Biologic medication for chemotherapy-induced neutropenia owned by Amgen Inc., the leading white blood cell stimulator for cancer patients.
pharmaceuticalsbiologicsoncology
Healthcare PharmaceuticalsOtezla
Owned by Amgen Inc.
Oral medication for psoriasis and psoriatic arthritis owned by Amgen Inc., the leading non-injectable treatment in its class.
pharmaceuticalspsoriasispsoriatic-arthritis
Healthcare PharmaceuticalsProlia
Owned by Amgen Inc.
Biologic osteoporosis medication owned by Amgen Inc., the leading injectable treatment for bone density loss.
pharmaceuticalsbiologicsosteoporosis
Amgen Ownership: Pros & Cons
Advantages
- +World's largest independent biotech with $36.8 billion diversified revenue
- +Biologics manufacturing expertise creates technical competitive barriers
- +10% revenue growth on 13% volume growth in FY2025
- +$7.3 billion R&D investment supports pipeline depth
- +Horizon acquisition adds rare disease growth under the brand
- +$8.1 billion free cash flow funds dividends and development
Considerations
- -IRA Medicare pricing is compressing economics on older products
- -Patent cliffs on aging blockbusters create revenue headwinds
- -Biosimilar competition erodes biologic exclusivity over time
- -Drug pricing scrutiny is political and persistent
- -Pipeline execution risk on emerging programs like obesity
Frequently Asked Questions About Amgen
Sources & Further Reading
Competitors to Amgen
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Amgen | USA (parent) | 2010 | Market leader | Global | All-ages | |
| Amgen | USA (parent) | 1998 | Market leader | Global | All-ages | |
| Amgen | USA (parent) | 2002 | Market leader | Global | All-ages | |
| Amgen | USA (parent) | 2014 | Market leader | Global | All-ages | |
| Pfizer | USA | 1849 | Premium | Global | All-ages | |
| Teva | Israel | 1901 | Leader | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsProlia
Owned by Amgen Inc.
Biologic osteoporosis medication owned by Amgen Inc., the leading injectable treatment for bone density loss.
pharmaceuticalsbiologicsosteoporosis
Healthcare PharmaceuticalsEnbrel
Owned by Amgen Inc.
Biologic medication for rheumatoid arthritis and autoimmune conditions, owned by Amgen Inc., one of the highest-selling drugs in pharmaceutical history.
pharmaceuticalsbiologicsrheumatoid-arthritis
Healthcare PharmaceuticalsNeulasta
Owned by Amgen Inc.
Biologic medication for chemotherapy-induced neutropenia owned by Amgen Inc., the leading white blood cell stimulator for cancer patients.
pharmaceuticalsbiologicsoncology
Healthcare PharmaceuticalsOtezla
Owned by Amgen Inc.
Oral medication for psoriasis and psoriatic arthritis owned by Amgen Inc., the leading non-injectable treatment in its class.
pharmaceuticalspsoriasispsoriatic-arthritis
Healthcare PharmaceuticalsPfizer
Owned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
pharmaceuticalvaccinesmedicines
Healthcare PharmaceuticalsTeva Pharmaceuticals
Owned by Teva Pharmaceutical Industries
Israeli multinational pharmaceutical company and the world's largest generic drug manufacturer, publicly traded on NYSE under ticker TEVA, headquartered in Tel Aviv, Israel.
generic-drugspharmaceuticalsspecialty-medicines
Competitive Analysis
Market Positioning: Amgen competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Amgen
Looking for brands with different ownership structures? These similar brands are not owned by Amgen Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsNovo Nordisk
Owned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
pharmaceuticalsdiabetesobesity
Publicly Traded
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsStryker
Owned by Stryker Corporation
Flagship medical technology brand of Stryker Corporation, founded in 1941 and a global leader in orthopaedic implants and surgical equipment.
medical-devicesorthopaedicssurgical-equipment
Publicly Traded
Stryker operates independently without a large parent corporation.
Healthcare PharmaceuticalsPfizer
Owned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
pharmaceuticalvaccinesmedicines
Publicly Traded
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsHCA Healthcare
Owned by HCA Healthcare, Inc.
HCA Healthcare is the flagship brand of the largest U.S. for-profit hospital operator, a network of 190 hospitals and about 2,500 ambulatory sites across 19 states and England.
hospitalshealthcareemergency-care
Publicly Traded
HCA Healthcare operates independently without a large parent corporation.
Healthcare PharmaceuticalsWalgreens
Owned by Walgreens Boots Alliance
Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.
pharmacydrugstoreretail-pharmacy
Privately Owned
Walgreens is privately owned, unlike Amgen which is under a publicly traded parent company.
Healthcare PharmaceuticalsAlcon
Owned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
eye-carecontact-lensesophthalmic
Publicly Traded
Alcon operates independently without a large parent corporation.
Amgen Inc. Stock Information
Jobs at Amgen Inc.
Latest News About Amgen
Related Articles About Amgen
View more articles
Brand Comparisons
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
Who Brands StaffMar 16, 2026
PharmaceuticalPfizerJohnson And Johnson
Brand Ownership
15 Pharmacy Brands and Their Corporate Parents
CVS spent $69 billion to buy Aetna. Walgreens acquired Boots for $15 billion. Amazon paid $1 billion for PillPack. Here are 15 pharmacy brands, who owns them, and how a once-diverse industry collapsed into two dominant players.
Who Brands StaffFeb 26, 2026
Pharmacy BrandsBrand OwnershipCvs
Brand Ownership
Who Owns Your Vitamins? The Hidden Corporate Parents Behind Supplement Brands
The supplement industry is worth $60+ billion but most brands are owned by pharma giants and food conglomerates. Here is who owns every major vitamin and supplement brand.
Who Brands StaffFeb 5, 2026
VitaminsSupplementsBrand Ownership
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription